Trending Topics in Gastroenterology
Explore current gastroenterology questions, clinical answers, and emerging research by topic.
Explore current gastroenterology questions, clinical answers, and emerging research by topic.
What Did the Study Find? This study developed baseline MRE-based scores to predict whether Crohn’s disease strictures would improve on subsequent imaging. The A-score incorporated bowel-wall thickness >6...
What Did the Study Find? Five-year results from the GALAXI-1 long-term extension evaluated the durability of guselkumab, an IL-23p19 inhibitor, through week 240. Among 87 patients remaining on...
What Did the Study Find? This prospective one-year study evaluated whether intestinal ultrasound (IUS) could predict sustained biologic effectiveness in 77 patients with IBD. Transmural remission was defined...
Introduction: Infliximab is an established rescue therapy for steroid-refractory acute severe ulcerative colitis (ASUC), but severe inflammation can accelerate drug clearance and reduce exposure. This study examined whether...
Introduction: Corticosteroids remain widely used for induction in moderate-to-severe UC, yet how quickly they should be tapered remains surprisingly uncertain. This Y-ECCO review examines an RCT comparing 10-week...
Introduction: Enteric infections can closely mimic an IBD flare, creating a difficult clinical question: infection or active inflammation? This meta-analysis evaluated whether stool multiplex PCR (MPCR) improves pathogen...
What Did the Study Find? PROFILE followed newly diagnosed Crohn’s disease patients originally randomized to top-down infliximab + immunomodulator or conventional step-up therapy. At ~5 years, Crohn’s-related surgery...
Introduction: Long-term durability and management of incomplete response are important when positioning IL-23 therapy in Crohn’s disease. VIVID-2 evaluated mirikizumab through 104 weeks, including IV reinduction in patients...
Introduction: Risankizumab, an IL-23p19 inhibitor, is an effective therapy for Crohn’s disease, but real-world outcomes in heavily pretreated patients are important for treatment positioning. RISANCROHN evaluated its effectiveness...
Introduction: Biologics are commonly used early in Crohn’s disease, while surgery is often reserved for complications or treatment failure. This meta-analysis compared early ileocaecal resection with biologic-first therapy...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.